Developer docs
API playgroundTry for free, no card

Search company profiles

VaRi bioscience

Full company profile

uuid003jj6c

Namestring
VaRi bioscience
Legal namestring
VaRi Bioscience GmbH
Company typeenum
Private
Founded yearint
2020
Descriptiontext

VaRi Bioscience GmbH is a development-stage women's health biotechnology company founded in 2020 and headquartered in Wildau, Germany, near Berlin. The company is developing a portfolio of vaginal ring drug delivery products targeting three indications: contraception (VR101, a non-invasive long-acting progestin-only ring for women with estrogen contraindications), vulvovaginal atrophy (VR102, a first-in-class long-acting local estrogen therapy ring), and endometriosis (VR103, a long-acting progestin therapy). The core technology is a proprietary polymer-based vaginal ring platform using EVA copolymer that releases active ingredients at predetermined rates over periods ranging from one month to five years via extrusion and ring-closure molding manufacturing processes.

The business model centers on pharmaceutical product sales upon regulatory approval across three addressable patient populations: approximately 40% of fertile women in the US with estrogen contraindications for contraception, approximately 36 million prevalent VVA cases across seven major markets, and roughly 10% of women of reproductive age affected by endometriosis. Pricing is not publicly disclosed as products remain in Phase I/II clinical trials. Manufacturing is outsourced to specialized Contract Manufacturing Organizations (CMOs) for clinical and commercial supply, allowing VaRi to focus internal resources on product development and regulatory activities. The company operates across Europe and North America and is currently privately held with one disclosed equity financing event from Aristo Pharma GmbH in December 2023.

VaRi Bioscience's competitive position rests on a senior management team drawn from Schering AG, Bayer, Organon, and Evestra, including multiple executives with 15-28 years of pharmaceutical R&D experience. The company publicly seeks additional financial and strategic investors to support growth, and is building its intellectual property portfolio around the vaginal ring platform technology. Distribution channels, pricing models, and commercial infrastructure are not yet established given the development-stage status, with commercialization likely dependent on out-licensing, partnership with larger pharmaceutical companies, or future direct launch once products receive regulatory approval.

Short descriptiontext

VaRi Bioscience GmbH is a development-stage German women's health biotechnology company founded in 2020, developing a pipeline of three vaginal ring products for contraception (VR101), vulvovaginal atrophy (VR102), and endometriosis (VR103) using proprietary polymer drug delivery technology.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersWildau, Germany
HQ citystring
Wildau
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
vaginal drug delivery, women's health therapeutics, long-acting contraceptives, polymer pharmaceutical formulations, hormone replacement therapy
Industry2 codes
PRIMARYHLAIACAN
Women’s Health & Reproductive Specialty Pharmaceuticals
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Women's Health Pharmaceuticals
Social media profiles1 record
Revenue model1 record
1Pharmaceutical Product Sales
TypeHardware Sales
Description

The company is developing vaginal ring products for women's health indications including contraception, vulvovaginal atrophy, and endometriosis. Revenue will be generated through product sales upon regulatory approval.

vari-bioscience.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

VaRi Bioscience develops a portfolio of vaginal ring pharmaceutical products for women's health indications, leveraging a proprietary polymer-based drug delivery platform. The technology releases active ingredients at predetermined rates over one month to five years and is being applied to three pipeline candidates: VR101 (long-acting progestin-only contraception), VR102 (local estrogen therapy for vulvovaginal atrophy), and VR103 (endometriosis therapy). Products are designed to provide non-invasive, long-term treatment with minimal systemic exposure, and are manufactured in partnership with specialized contract manufacturing organizations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • VR101 shows superior contraceptive efficacy compared to oral progestin-only products (POPs) by avoiding peak-trough plasma variations
+2 more records
Product overview1 text field

VaRi Bioscience is a biotech company developing a portfolio of vaginal ring products for women's health indications. The core platform is the women's-specific vaginal ring drug delivery technology that enables long-term treatment with minimal systemic exposure. Current pipeline includes three products: VR101 (progestin-only contraceptive), VR102 (local estrogen therapy for vulvovaginal atrophy), and VR103 (endometriosis therapy). The technology bypasses first-pass metabolism in the liver, allowing for lower drug doses and improved tolerability.

Product and service1 record
1VR101
Partnership1 partner
1Contract Manufacturing Organizations (CMOs)
Strategic tierCoreTypeOthers
Description

VaRi Bioscience collaborates with specialized CMOs for clinical and commercial supply of vaginal ring products. The company is collaborating with specialized CMOs for manufacturing while focusing on product development and regulatory activities.

vari-bioscience.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

European women's health specialty pharma (acquired by Perrigo) focused on reproductive health and emergency contraception. Mid-size comparable to VaRi's likely commercial ambition and target specialty prescribing audience.

TypeBroad incumbent
Description

Major women's health franchise post-Allergan acquisition including Lo Loestrin and Oriahnn for endometriosis. Competes head-to-head with VaRi's VR103 in endometriosis and has substantially greater commercial reach.

TypeDirect peer
Description

Belgian specialty pharma developing women's health products including vaginal ring contraceptives (Estelle) and vaginal hormone therapy (Donesta). Most direct competitor to VaRi's vaginal ring platform approach, with overlapping indication set and similar combination drug-device regulatory pathway.

TypeDirect peer
Description

Clinical-stage women's health biotech developing novel therapies in contraception, vaginal health, and reproductive medicine. Closely comparable business stage and indication set to VaRi, with similar capital-intensive biotech economics and platform-extension strategy.

TypeBroad incumbent
Description

Global pharma major with one of the largest women's health franchises (oral contraceptives, IUDs, endometriosis therapies). Several VaRi founders worked at Bayer/Schering, and Bayer's portfolio overlaps VaRi's endometriosis and contraception indications directly.

TypeEmerging player
Description

Women's health specialty company commercializing Phexxi, a non-hormonal contraceptive vaginal gel. Overlapping commercial call point (OB/GYNs and women's health providers) and reproductive health focus, though different mechanism.

TypeEmerging player
Description

Women's health company with Twirla, a combination hormonal contraceptive patch, demonstrating late-stage regulatory pathway in women's health drug delivery. Comparable regulatory and commercial-readiness profile to VaRi's intended path.

TypeDirect peer
Description

US women's health specialty pharma (acquired by Mayne Pharma) focused on hormone therapies including vulvovaginal atrophy treatments. Direct overlap with VaRi's VR102 indication and similar prescription-driven commercial model targeting OB/GYNs.

TypeBroad incumbent
Description

Global pharma with broad women's health portfolio across contraception, menopause, and endometriosis (via legacy Pharmacia Upjohn assets). Potential acquirer given overlap with VaRi's indication set.

TypeBroad incumbent
Description

Global women's health spinoff from Merck that markets NuvaRing, the leading commercialized contraceptive vaginal ring. Head of Product Development Herman Vromans spent 20+ years at Organon/Schering Plough/Merck. Sets the commercial benchmark VaRi's VR101 must beat.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

VaRi bioscience

Women's Health Pharmaceuticalsvari-bioscience.com

VaRi Bioscience GmbH is a development-stage German women's health biotechnology company founded in 2020, developing a pipeline of three vaginal ring products for contraception (VR101), vulvovaginal atrophy (VR102), and endometriosis (VR103) using proprietary polymer drug delivery technology.

What VaRi bioscience does

VaRi Bioscience GmbH is a development-stage women's health biotechnology company founded in 2020 and headquartered in Wildau, Germany, near Berlin. The company is developing a portfolio of vaginal ring drug delivery products targeting three indications: contraception (VR101, a non-invasive long-acting progestin-only ring for women with estrogen contraindications), vulvovaginal atrophy (VR102, a first-in-class long-acting local estrogen therapy ring), and endometriosis (VR103, a long-acting progestin therapy). The core technology is a proprietary polymer-based vaginal ring platform using EVA copolymer that releases active ingredients at predetermined rates over periods ranging from one month to five years via extrusion and ring-closure molding manufacturing processes.

The business model centers on pharmaceutical product sales upon regulatory approval across three addressable patient populations: approximately 40% of fertile women in the US with estrogen contraindications for contraception, approximately 36 million prevalent VVA cases across seven major markets, and roughly 10% of women of reproductive age affected by endometriosis. Pricing is not publicly disclosed as products remain in Phase I/II clinical trials. Manufacturing is outsourced to specialized Contract Manufacturing Organizations (CMOs) for clinical and commercial supply, allowing VaRi to focus internal resources on product development and regulatory activities. The company operates across Europe and North America and is currently privately held with one disclosed equity financing event from Aristo Pharma GmbH in December 2023.

VaRi Bioscience's competitive position rests on a senior management team drawn from Schering AG, Bayer, Organon, and Evestra, including multiple executives with 15-28 years of pharmaceutical R&D experience. The company publicly seeks additional financial and strategic investors to support growth, and is building its intellectual property portfolio around the vaginal ring platform technology. Distribution channels, pricing models, and commercial infrastructure are not yet established given the development-stage status, with commercialization likely dependent on out-licensing, partnership with larger pharmaceutical companies, or future direct launch once products receive regulatory approval.

VaRi bioscience firmographics

Firmographics
Name
VaRi bioscience
Legal name
VaRi Bioscience GmbH
Website
https://vari-bioscience.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
VaRi Bioscience GmbH is a development-stage German women's health biotechnology company founded in 2020, developing a pipeline of three vaginal ring products for contraception (VR101), vulvovaginal atrophy (VR102), and endometriosis (VR103) using proprietary polymer drug delivery technology.
Ownership category
akta.pro rank

VaRi bioscience industry classification

Industry
Product category
Women's Health Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAN
Women’s Health & Reproductive Specialty Pharmaceuticals
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Vaginal drug delivery
  • Women's health therapeutics
  • Long-acting contraceptives
  • Polymer pharmaceutical formulations
  • Hormone replacement therapy

Where VaRi bioscience is headquartered

Location

Headquarters

HQ city
Wildau
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

VaRi bioscience business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: The company is developing vaginal ring products for women's health indications including contraception, vulvovaginal atrophy, and endometriosis. Revenue will be generated through product sales upon regulatory approval.

Distribution channels1 record

Marketing channels4 records

VaRi bioscience product offering

Product offering

Core offering

VaRi Bioscience develops a portfolio of vaginal ring pharmaceutical products for women's health indications, leveraging a proprietary polymer-based drug delivery platform. The technology releases active ingredients at predetermined rates over one month to five years and is being applied to three pipeline candidates: VR101 (long-acting progestin-only contraception), VR102 (local estrogen therapy for vulvovaginal atrophy), and VR103 (endometriosis therapy). Products are designed to provide non-invasive, long-term treatment with minimal systemic exposure, and are manufactured in partnership with specialized contract manufacturing organizations.

Product overview

VaRi Bioscience is a biotech company developing a portfolio of vaginal ring products for women's health indications. The core platform is the women's-specific vaginal ring drug delivery technology that enables long-term treatment with minimal systemic exposure. Current pipeline includes three products: VR101 (progestin-only contraceptive), VR102 (local estrogen therapy for vulvovaginal atrophy), and VR103 (endometriosis therapy). The technology bypasses first-pass metabolism in the liver, allowing for lower drug doses and improved tolerability.

Differentiator

Problem solved

Functional benefit

Products and services

  • VR101

Quantifiable outcome

  • VR101 shows superior contraceptive efficacy compared to oral progestin-only products (POPs) by avoiding peak-trough plasma variations
  • +2 more outcomes

Companies that use VaRi bioscience

Customer profile

Segments3 records

Ideal customer profiles3 records

VaRi bioscience technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

VaRi bioscience partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Contract Manufacturing Organizations (CMOs)coreOthersVaRi Bioscience collaborates with specialized CMOs for clinical and commercial supply of vaginal ring products. The company is collaborating with specialized CMOs for manufacturing while focusing on product development and regulatory activities.

Recent moves6 records

Expansion highlights5 records

VaRi bioscience competitors and assessment

Company assessment

Direct peers

  • HRA Pharma: European women's health specialty pharma (acquired by Perrigo) focused on reproductive health and emergency contraception. Mid-size comparable to VaRi's likely commercial ambition and target specialty prescribing audience.
  • Mithra Pharmaceuticals: Belgian specialty pharma developing women's health products including vaginal ring contraceptives (Estelle) and vaginal hormone therapy (Donesta). Most direct competitor to VaRi's vaginal ring platform approach, with overlapping indication set and similar combination drug-device regulatory pathway.
  • Daré Bioscience: Clinical-stage women's health biotech developing novel therapies in contraception, vaginal health, and reproductive medicine. Closely comparable business stage and indication set to VaRi, with similar capital-intensive biotech economics and platform-extension strategy.
  • TherapeuticsMD (now Mayne Pharma): US women's health specialty pharma (acquired by Mayne Pharma) focused on hormone therapies including vulvovaginal atrophy treatments. Direct overlap with VaRi's VR102 indication and similar prescription-driven commercial model targeting OB/GYNs.

Broad incumbents

  • AbbVie: Major women's health franchise post-Allergan acquisition including Lo Loestrin and Oriahnn for endometriosis. Competes head-to-head with VaRi's VR103 in endometriosis and has substantially greater commercial reach.
  • Bayer AG: Global pharma major with one of the largest women's health franchises (oral contraceptives, IUDs, endometriosis therapies). Several VaRi founders worked at Bayer/Schering, and Bayer's portfolio overlaps VaRi's endometriosis and contraception indications directly.
  • Pfizer: Global pharma with broad women's health portfolio across contraception, menopause, and endometriosis (via legacy Pharmacia Upjohn assets). Potential acquirer given overlap with VaRi's indication set.
  • Organon & Co. Global women's health spinoff from Merck that markets NuvaRing, the leading commercialized contraceptive vaginal ring. Head of Product Development Herman Vromans spent 20+ years at Organon/Schering Plough/Merck. Sets the commercial benchmark VaRi's VR101 must beat.

Emerging players

  • Evofem Biosciences: Women's health specialty company commercializing Phexxi, a non-hormonal contraceptive vaginal gel. Overlapping commercial call point (OB/GYNs and women's health providers) and reproductive health focus, though different mechanism.
  • Agile Therapeutics: Women's health company with Twirla, a combination hormonal contraceptive patch, demonstrating late-stage regulatory pathway in women's health drug delivery. Comparable regulatory and commercial-readiness profile to VaRi's intended path.

Market position

Strengths1 record

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

VaRi bioscience social profiles

Digital presence

VaRi bioscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

VaRi bioscience leadership team

Management profile

Number of profiles

Profiles5 records

VaRi bioscience funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

VaRi bioscience M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VaRi bioscience

What does VaRi bioscience do?

VaRi Bioscience develops a portfolio of vaginal ring pharmaceutical products for women's health indications, leveraging a proprietary polymer-based drug delivery platform. The technology releases active ingredients at predetermined rates over one month to five years and is being applied to three pipeline candidates: VR101 (long-acting progestin-only contraception), VR102 (local estrogen therapy for vulvovaginal atrophy), and VR103 (endometriosis therapy). Products are designed to provide non-invasive, long-term treatment with minimal systemic exposure, and are manufactured in partnership with specialized contract manufacturing organizations.

Is VaRi bioscience a public or private company?

VaRi bioscience is a private company. It is classified as venture growth investor backed and is currently operating.

When was VaRi bioscience founded?

VaRi bioscience was founded in 2020. It employs 1 to 10 people.

Where is VaRi bioscience based?

VaRi bioscience is headquartered in Wildau, Germany, in the Europe region.

How does VaRi bioscience make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are VaRi bioscience's main competitors?

Direct peers on record are HRA Pharma, Mithra Pharmaceuticals, Daré Bioscience and TherapeuticsMD (now Mayne Pharma). Broad incumbents are AbbVie, Bayer AG, Pfizer and Organon & Co.. Emerging players are Evofem Biosciences and Agile Therapeutics.

Does VaRi bioscience have an API?

No public API is recorded for VaRi bioscience.

What industry is VaRi bioscience in?

VaRi bioscience's product category is Women's Health Pharmaceuticals. Its primary akta.pro industry code is HLAIACAN, Women’s Health & Reproductive Specialty Pharmaceuticals, with a secondary code of HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales